Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 82.50% | 78.00% | 64.00% | 299.58% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 82.50% | 78.00% | 64.00% | 299.58% | -- |
| Cost of Revenue | -82.71% | -59.41% | -22.53% | 136.86% | -- |
| Gross Profit | 426.26% | 545.00% | -- | -- | -- |
| SG&A Expenses | -48.81% | -46.23% | -43.94% | -43.04% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 63.02% | 85.31% | 92.44% | 84.07% | -- |
| Total Operating Expenses | -37.20% | -42.30% | -45.47% | -55.18% | -- |
| Operating Income | 38.48% | 43.04% | 45.80% | 55.57% | -- |
| Income Before Tax | 31.56% | 63.68% | 72.94% | 75.49% | -- |
| Income Tax Expenses | -- | -2,981.82% | -203.49% | -203.49% | -- |
| Earnings from Continuing Operations | 31.05% | 63.84% | 73.22% | 75.72% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.05% | 63.84% | 73.22% | 75.72% | -- |
| EBIT | 38.48% | 43.04% | 45.80% | 55.57% | -- |
| EBITDA | 38.83% | 43.67% | 46.39% | 56.45% | -- |
| EPS Basic | 57.50% | 76.75% | 81.56% | 80.65% | -- |
| Normalized Basic EPS | 63.09% | 62.97% | 62.73% | 63.68% | -- |
| EPS Diluted | 57.50% | 76.75% | 81.56% | 80.65% | -- |
| Normalized Diluted EPS | 63.09% | 62.97% | 62.73% | 63.68% | -- |
| Average Basic Shares Outstanding | 62.00% | 59.45% | 56.55% | 33.55% | -- |
| Average Diluted Shares Outstanding | 62.00% | 59.45% | 56.55% | 33.55% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |